Insulin icodec offers a reduction in dosing frequency of injectable therapies to once weekly, which may improve convenience, adherence, and quality of life over once-daily basal insulin analogs. In this touchENDOCRINOLOGY interview, Prof. Chantal Mathieu (University Hospital Gasthuisberg Leuven, Leuven, Belgium) discusses the limitations of once daily basal insulin analogues and gives an overview on insulin icodec.
The abstract entitled: ‘Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Combination with Bolus Insulin in Individuals with Type 2 Diabetes on Basal-Bolus Regimens (ONWARDS 4)‘ was presented at the 22nd Annual Diabetes Technology Meeting, 03-05 Nov, 2022.
- What are the limitations of once daily basal insulin analogues? (0:20)
- What is insulin icodec and what is the basis for its long half-life? (2:40)
Disclosures: Chantal Mathieu has received grant/research support from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics.
Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.
Recorded as a highlight of DTM 2022
Share this Video
Related Videos In Diabetes
José García-Tirado, DTM 2022: RocketAP in Practice: Results from Pilot and Feasibility Trials
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of the Rocket AP will be. The abstract entitled: ‘RocketAP in Practice: Results from Pilot and Feasibility […]
José García-Tirado, DTM 2022: Challenges in the development of artificial pancreas systems
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses the major challenges in the development of artificial pancreas systems. The abstract entitled: ‘RocketAP in Practice: Results from Pilot […]
Carol Levy, DTM 2022: The use of Control-IQ technology in prior MDI and basal-only insulin users with type 2 diabetes
In this touchENDOCRINOLOGY interview, Prof. Carol Levy (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) discusses her study which evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology to show that Control-IQ technology could offer considerable benefit to individuals with type 2 diabetes. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!